<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="15/05/2006" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=10101034" creator="Yo Shidahara">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>10101034</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term sem="Other" id="T58">Inhibition</term> of <term sem="Other" id="T1" lex="cyclooxygenase-2_expression"><term sem="Protein_molecule" id="T2" lex="cyclooxygenase-2">cyclooxygenase-2</term> expression</term> by <term sem="Organic_compound_other" id="T3" lex="4-trifluoromethyl_derivative">4-trifluoromethyl derivatives</term> of <term sem="Organic_compound_other" id="T4" lex="salicylate">salicylate</term>, <term sem="Organic_compound_other" id="T5" lex="triflusal">triflusal</term>, and its <term sem="Organic_compound_other" id="T6" lex="deacetylated_metabolite">deacetylated metabolite</term>, <term sem="Organic_compound_other" id="T7" lex="2-hydroxy-4-trifluoromethylbenzoic_acid">2-hydroxy-4-trifluoromethylbenzoic acid</term>.</sentence>
<event id="E1">
<type class="Gene_expression" />
<theme idref="T2" />
<clue>Inhibition of cyclooxygenase-2 <clueType>expression</clueType> by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.</clue>
</event>
<event id="E2">
<type class="Negative_regulation" />
<theme idref="E1" />
<cause idref="T5" />
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> cyclooxygenase-2 expression <linkCause>by</linkCause> 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.</clue>
</event>
<event id="E3">
<type class="Negative_regulation" />
<theme idref="E1" />
<cause idref="T7" />
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> cyclooxygenase-2 expression <linkCause>by</linkCause> 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">The therapeutic potential of drugs that block the induction of <term sem="Protein_molecule" id="T8" lex="cyclooxygenase-2">cyclooxygenase-2</term> has been emphasized.</sentence>
<sentence id="S3">When two <term sem="Organic_compound_other" id="T9" lex="4-trifluoromethyl_salicylate_derivative">4-trifluoromethyl salicylate derivatives</term> [<term sem="Organic_compound_other" id="T10" lex="2-acetoxy-4-trifluoromethyl-benzoic_acid">2-acetoxy-4-trifluoromethyl-benzoic acid</term> (<term sem="Organic_compound_other" id="T11" lex="triflusal">triflusal</term>) and its <term sem="Organic_compound_other" id="T12" lex="deacetylated_metabolite">deacetylated metabolite</term> <term sem="Organic_compound_other" id="T13" lex="2-hydroxy-4-trifluoromethylbenzoic_acid">2-hydroxy-4-trifluoromethylbenzoic acid</term> (<term sem="Organic_compound_other" id="T14" lex="HTB">HTB</term>)] were compared with aspirin and sodium salicylate as <term sem="Protein_molecule" id="T15" lex="cyclooxygenase-2">cyclooxygenase-2</term> (COX-2) inhibitors, we observed that in <term sem="Tissue_natural" id="T16" lex="bacterial_lipopolysaccharide-activated_human_blood">bacterial lipopolysaccharide-activated human blood</term>, <term sem="Organic_compound_other" id="T17" lex="triflusal">triflusal</term>, <term sem="Organic_compound_other" id="T18" lex="aspirin">aspirin</term>, and <term sem="Organic_compound_other" id="T19" lex="HTB">HTB</term>, but not <term sem="Organic_compound_other" id="T20" lex="sodium_salicylate">sodium salicylate</term>, inhibited <term sem="Protein_molecule" id="A2">COX-2</term>-mediated <term sem="Other" id="T22"><term sem="Organic_compound_other" id="A3">prostaglandin E2</term> (<term sem="Organic_compound_other" id="T23" lex="PGE2">PGE2</term>) production</term> (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</sentence>
<event id="E6">
<type class="Metabolism" />
<theme idref="T23" />
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that in bacterial lipopolysaccharide-activated human blood, triflusal, aspirin, and HTB, but not sodium salicylate, inhibited COX-2-mediated prostaglandin E2 (PGE2) <clueType>production</clueType> (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<event id="E7">
<type class="Positive_regulation" />
<theme idref="E6" />
<cause idref="A2" />
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that in bacterial lipopolysaccharide-activated human blood, triflusal, aspirin, and HTB, but not sodium salicylate, inhibited COX-2-<clueType>mediated</clueType> prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<event id="E8">
<type class="Negative_regulation" />
<theme idref="E7" />
<cause idref="T17" />
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that <clueLoc>in bacterial lipopolysaccharide-activated human blood</clueLoc>, triflusal, aspirin, and HTB, but not sodium salicylate, <clueType>inhibited</clueType> COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<event id="E9">
<type class="Negative_regulation" />
<theme idref="E7" />
<cause idref="T18" />
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that <clueLoc>in bacterial lipopolysaccharide-activated human blood</clueLoc>, triflusal, aspirin, and HTB, but not sodium salicylate, <clueType>inhibited</clueType> COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<event id="E10">
<type class="Negative_regulation" />
<theme idref="E7" />
<cause idref="T19" />
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that <clueLoc>in bacterial lipopolysaccharide-activated human blood</clueLoc>, triflusal, aspirin, and HTB, but not sodium salicylate, <clueType>inhibited</clueType> COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<event assertion="non-exist" id="E11">
<type class="Negative_regulation" />
<theme idref="E7" />
<cause idref="T17" />
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that <clueLoc>in bacterial lipopolysaccharide-activated human blood</clueLoc>, triflusal, aspirin, and HTB, but not sodium salicylate, <clueType>inhibited</clueType> COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<sentence id="S4">However, only <term sem="Organic_compound_other" id="T24" lex="triflusal">triflusal</term> and <term sem="Organic_compound_other" id="T25" lex="aspirin">aspirin</term> inhibited purified <term sem="Protein_molecule" id="T26">COX-2 enzyme</term>.</sentence>
<event id="E12">
<type class="Negative_regulation" />
<theme idref="T26" />
<cause idref="T24" />
<clue>However, only triflusal and aspirin <clueType>inhibited</clueType> purified COX-2 enzyme.</clue>
</event>
<event id="E13">
<type class="Negative_regulation" />
<theme idref="T26" />
<cause idref="T25" />
<clue>However, only triflusal and aspirin <clueType>inhibited</clueType> purified COX-2 enzyme.</clue>
</event>
<sentence id="S5">To test this apparent discrepancy, we realized that <term sem="Organic_compound_other" id="T27" lex="HTB">HTB</term> and <term sem="Organic_compound_other" id="T28" lex="triflusal">triflusal</term> (but neither <term sem="Organic_compound_other" id="T29" lex="aspirin">aspirin</term> nor <term sem="Organic_compound_other" id="T30" lex="salicylate">salicylate</term>) produced a concentration-dependent inhibition of <term sem="Other" id="T31" lex="COX-2_protein_expression"><term sem="Protein_molecule" id="T32">COX-2 protein</term> expression</term> in <term sem="Cell_natural" id="T33" lex="peripheral_human_mononuclear_cell">peripheral human mononuclear cells</term>.</sentence>
<event id="E14">
<type class="Gene_expression" />
<theme idref="T32" />
<clue>To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) produced a concentration-dependent inhibition of COX-2 protein <clueType>expression</clueType> in peripheral human mononuclear cells.</clue>
</event>
<event id="E15">
<type class="Negative_regulation" />
<theme idref="E14" />
<clue>To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) produced a concentration-dependent <clueType>inhibition</clueType> <linkTheme>of</linkTheme> COX-2 protein expression in peripheral human mononuclear cells.</clue>
</event>
<event id="E16">
<type class="Positive_regulation" />
<theme idref="E15" />
<cause idref="T27" />
<clue>To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) <clueType>produced</clueType> a concentration-dependent inhibition of COX-2 protein expression <clueLoc>in peripheral human mononuclear cells</clueLoc>.</clue>
</event>
<event id="E17">
<type class="Positive_regulation" />
<theme idref="E15" />
<cause idref="T28" />
<clue>To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) <clueType>produced</clueType> a concentration-dependent inhibition of COX-2 protein expression <clueLoc>in peripheral human mononuclear cells</clueLoc>.</clue>
</event>
<event assertion="non-exist" id="E18">
<type class="Positive_regulation" />
<theme idref="E15" />
<cause idref="T29" />
<clue>To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) <clueType>produced</clueType> a concentration-dependent inhibition of COX-2 protein expression <clueLoc>in peripheral human mononuclear cells</clueLoc>.</clue>
</event>
<event assertion="non-exist" id="E19">
<type class="Positive_regulation" />
<theme idref="E15" />
<cause idref="T30" />
<clue>To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) <clueType>produced</clueType> a concentration-dependent inhibition of COX-2 protein expression <clueLoc>in peripheral human mononuclear cells</clueLoc>.</clue>
</event>
<sentence id="S6">This observation was further confirmed in a <term sem="Other" id="T34" lex="rat_air_pouch_model">rat air pouch model</term> in vivo, in which both <term sem="Organic_compound_other" id="T35" lex="aspirin">aspirin</term> and <term sem="Organic_compound_other" id="T36" lex="triflusal">triflusal</term> inhibited <term sem="Other" id="T37" lex="PGE2_production"><term sem="Organic_compound_other" id="T38" lex="PGE2">PGE2</term> production</term> (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only <term sem="Multicellular_organism_natural" id="T39" lex="triflusal-treated_animal"><term sem="Organic_compound_other" id="T40" lex="triflusal">triflusal</term>-treated animals</term> showed a decrease in <term sem="Other" id="T41" lex="COX-2_expression"><term sem="Protein_molecule" id="T42" lex="COX-2">COX-2</term> expression</term>.</sentence>
<event id="E20">
<type class="Metabolism" />
<theme idref="T38" />
<clue>This observation was further confirmed in a rat air pouch model in vivo, in which both aspirin and triflusal inhibited PGE2 <clueType>production</clueType> (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 expression.</clue>
</event>
<event id="E21">
<type class="Negative_regulation" />
<theme idref="E20" />
<cause idref="T35" />
<clue>This observation was further confirmed <clueLoc>in a rat air pouch model</clueLoc> in vivo, in which both aspirin and triflusal <clueType>inhibited</clueType> PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 expression.</clue>
</event>
<event id="E22">
<type class="Negative_regulation" />
<theme idref="E20" />
<cause idref="T36" />
<clue>This observation was further confirmed <clueLoc>in a rat air pouch model</clueLoc> in vivo, in which both aspirin and triflusal <clueType>inhibited</clueType> PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 expression.</clue>
</event>
<event id="E24">
<type class="Gene_expression" />
<theme idref="T42" />
<clue>This observation was further confirmed in a rat air pouch model in vivo, in which both aspirin and triflusal inhibited PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 <clueType>expression</clueType>.</clue>
</event>
<event id="E25">
<type class="Negative_regulation" />
<theme idref="E24" />
<cause idref="T40" />
<clue>This observation was further confirmed in a rat air pouch model in vivo, in which both aspirin and triflusal inhibited PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-<linkCause>treated</linkCause> <clueLoc>animals</clueLoc> showed a <clueType>decrease</clueType> <linkTheme>in</linkTheme> COX-2 expression.</clue>
</event>
<sentence id="S7">This different behavior may be, at least in part, due to the ability of <term sem="Organic_compound_other" id="T43" lex="HTB">HTB</term> and <term sem="Organic_compound_other" id="T44" lex="triflusal">triflusal</term> to block the activation of the transcription factor <term sem="Protein_complex" id="T45" lex="nuclear_factor-kappaB">nuclear factor-kappaB</term> to a higher extent than <term sem="Organic_compound_other" id="T46" lex="aspirin">aspirin</term> and <term sem="Organic_compound_other" id="T47" lex="sodium_salicylate">sodium salicylate</term>.</sentence>
<event id="E26">
<type class="Positive_regulation" />
<theme idref="T45" />
<clue>This different behavior may be, at least in part, due to the ability of HTB and triflusal to block the <clueType>activation</clueType> <linkTheme>of</linkTheme> the transcription factor nuclear factor-kappaB to a higher extent than aspirin and sodium salicylate.</clue>
</event>
<event id="E27">
<type class="Negative_regulation" />
<theme idref="E26" />
<cause idref="T43" />
<clue>This different behavior may be, at least in part, due to the ability of HTB and triflusal to <clueType>block</clueType> the activation of the transcription factor nuclear factor-kappaB to a higher extent than aspirin and sodium salicylate.</clue>
</event>
<event id="E28">
<type class="Negative_regulation" />
<theme idref="E26" />
<cause idref="T44" />
<clue>This different behavior may be, at least in part, due to the ability of HTB and triflusal to <clueType>block</clueType> the activation of the transcription factor nuclear factor-kappaB to a higher extent than aspirin and sodium salicylate.</clue>
</event>
<sentence id="S8">Thus, in addition to inhibiting the <term sem="Other" id="T48" lex="COX-2_activity"><term sem="Protein_molecule" id="T21">COX-2</term> activity</term> at therapeutic concentrations, <term sem="Organic_compound_other" id="T49" lex="triflusal">triflusal</term> is able to block through its metabolite <term sem="Organic_compound_other" id="T50" lex="HTB">HTB</term> the expression of new enzyme, and hence the resumption of <term sem="Other" id="T51" lex="PGE2_synthesis"><term sem="Organic_compound_other" id="T52" lex="PGE2">PGE2</term> synthesis</term>.</sentence>
<event id="E29">
<type class="Negative_regulation" />
<theme idref="T48" />
<cause idref="T49" />
<clue>Thus, in addition to <clueType>inhibiting</clueType> the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 synthesis.</clue>
</event>
<event id="E30">
<type class="Gene_expression" />
<theme idref="T42" />
<clue>Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the <clueType>expression</clueType> <linkTheme>of</linkTheme> <corefTheme>new enzyme</corefTheme>, and hence the resumption of PGE2 synthesis.</clue>
</event>
<event id="E31">
<type class="Negative_regulation" />
<theme idref="E30" />
<cause idref="T50" />
<clue>Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to <clueType>block</clueType> <linkCause>through</linkCause> its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 synthesis.</clue>
</event>
<event id="E32">
<type class="Metabolism" />
<theme idref="T52" />
<clue>Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 <clueType>synthesis</clueType>.</clue>
</event>
<event id="E33">
<type class="Positive_regulation" />
<theme idref="E32" />
<clue>Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the expression of new enzyme, and hence the <clueType>resumption</clueType> of PGE2 synthesis.</clue>
</event>
<event id="E34">
<type class="Negative_regulation" />
<theme idref="E33" />
<cause idref="T50" />
<clue>Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to <clueType>block</clueType> <linkCause>through</linkCause> its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 synthesis.</clue>
</event>
<sentence id="S9"><term sem="Organic_compound_other" id="T53" lex="triflusal">Triflusal</term> and <term sem="Organic_compound_other" id="T54" lex="HTB">HTB</term> may exert beneficial effects in <term sem="Other" id="A6">processes</term> in which de novo <term sem="Other" id="T55" lex="COX-2_expression"><term sem="Protein_molecule" id="T56" lex="COX-2">COX-2</term> expression</term> is involved and, in a broader sense, in <term sem="Other" id="A5">pathological situations</term> in which <term sem="DNA_domain_or_region" id="A4">genes</term> under <term sem="Protein_complex" id="T57" lex="nuclear_factor-kappaB">nuclear factor-kappaB</term> control are up-regulated.</sentence>
<event id="E35">
<type class="Gene_expression" />
<theme idref="T56" />
<clue>Triflusal and HTB may exert beneficial effects in processes in which de novo COX-2 <clueType>expression</clueType> is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event id="E42">
<type class="Correlation" />
<theme idref="E35" />
<theme idref="A6" />
<clue>Triflusal and HTB may exert beneficial effects in processes <linkTheme>in which</linkTheme> de novo COX-2 expression is <clueType>involved</clueType> and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event id="E36">
<type class="Regulation" />
<theme idref="A6" />
<cause idref="T53" />
<clue>Triflusal and HTB may exert beneficial <clueType>effects</clueType> <linkTheme>in</linkTheme> processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event id="E37">
<type class="Regulation" />
<theme idref="A6" />
<cause idref="T54" />
<clue>Triflusal and HTB may exert beneficial <clueType>effects</clueType> <linkTheme>in</linkTheme> processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event id="E38">
<type class="Regulation" />
<theme idref="A4" />
<cause idref="T57" />
<clue>Triflusal and HTB may exert beneficial effects in processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB <clueType>control</clueType> are up-regulated.</clue>
</event>
<event id="E39">
<type class="Positive_regulation" />
<theme idref="E38" />
<clue>Triflusal and HTB may exert beneficial effects in processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event id="E40">
<type class="Regulation" />
<theme idref="A5" />
<cause idref="T53" />
<clue>Triflusal and HTB may exert beneficial <clueType>effects</clueType> in processes in which de novo COX-2 expression is involved and, in a broader sense, <linkTheme>in</linkTheme> pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event id="E41">
<type class="Regulation" />
<theme idref="A5" />
<cause idref="T54" />
<clue>Triflusal and HTB may exert beneficial <clueType>effects</clueType> in processes in which de novo COX-2 expression is involved and, in a broader sense, <linkTheme>in</linkTheme> pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
